Arthritis - Healing Genes


Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Conventional Platelet-Rich Plasma Versus Concentrated Bone Marrow Stem Cell Injections for Osteoarthritis of the Knee

A Randomized, Single-Blinded, Controlled Trial Comparing Conventional Platelet Rich Plasma (PRP) to Concentrated Bone Marrow Aspirate (BMAC) for Osteoarthritis of the Knee

Phase 2


The Mayo Clinic in Florida is conducting a trial comparing two treatments for osteoarthritis of the knee: injections of bone marrow aspirate concentrate (BMAC) stem cells taken from the patient’s hip bone, and injections of platelet-rich plasma drawn by IV. Both treatments are delivered directly into the knee. Follow up will be needed at 1 week, 6 weeks, 6 months, and 12 months after the injections, plus X-rays before the treatment and at 12 months.


  • Be 18 years of age and older
  • Have a diagnosis of osteoarthritis in both legs and pain in one knee meeting certain grades
  • Subjects must have previously tried 6 weeks of one of the following conservative treatments: Activity modification, weight loss, physical therapy, anti-inflammatory, or injection therapy
  • Not be pregnant or breastfeeding


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Recovery of the plasma or bone marrow aspirate. Each require a short hospital visit, though the bone marrow aspirate is a more complex procedure.
  3. Follow up will be needed at 1 week, 6 weeks, 6 months, and 12 months after the injections, plus X-rays before the treatment and at 12 months.


The study site is at the Mayo Clinic in Jacksonville, FL. Map.


Shane Shapiro, MD  |  (904) 953-2496  |  [email protected]




Mayo Clinic


Or go online:


Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader